Manas AI, a full-stack, AI-driven company focused on discovering and advancing next-generation medicines, is proud to announce the appointment of Jonathan Baell, PhD, as Chief Scientific Officer (CSO). Dr. Baell, a world-renowned medicinal chemist with over 20 years of experience in drug discovery and development, will lead Manas AI's scientific strategy and research initiatives.
Dr. Baell joins Manas AI following an illustrious career in medicinal chemistry and translational research. As Executive Director of Discovery Chemistry at Lyterian Therapeutics, he spearheaded innovative drug discovery programs across multiple therapeutic areas. Previously, Dr. Baell was the Founding Director of the Australian Translational Medicinal Chemistry Facility (ATMCF), where he transformed it into a multimillion-dollar enterprise that fostered multiple spin-out companies and licensing deals. His contributions to clinical outcomes include discoveries of anti-cancer BCL2-family inhibitors and anti-anxiety GPCR modulators. Globally recognized as the architect of PAINS (Pan Assay Interference Compounds), he has reshaped scientific policies and practices, amassing over 80 patents, 200 publications, and 15,000 citations, which solidifies his impact on the field of medicinal chemistry.
“We are excited to welcome Dr. Jonathan Baell as our Chief Scientific Officer,” said Dr. Siddhartha Mukherjee, CEO and Co-Founder of Manas AI. “Dr. Baell’s groundbreaking contributions to medicinal chemistry and drug discovery, coupled with his visionary leadership, align perfectly with our mission to revolutionize therapeutics through AI-driven innovation. We are confident that his expertise will propel Manas AI to new heights.”
“Joining Manas AI feels like a perfect alignment of the stars. My experience and skills seamlessly compliment the company's aspirations, and I am eager to contribute to the exceptional team being formed under the leadership of the inspiring CEO, Dr. Siddhartha Mukherjee,” said Baell. “I see a universe of innovation on the horizon for Manas AI.”
Dr. Baell holds significant editorial and societal positions, including Senior Editor of “Future Medicinal Chemistry” and the Chair of the Board of the International Chemical Biology Society. He also serves on the scientific or strategic advisory board of several national and international biotechnology companies.
About Manas AI
Manas AI is a full-stack, AI-driven drug discovery company. By harnessing the power of proprietary AI models and leveraging extensive computational infrastructure, the company aims to dramatically reduce drug discovery timelines. Co-founded by Dr. Siddhartha Mukherjee and Reid Hoffman, and a world-class interdisciplinary team that spans AI, computational chemistry, biology, and clinical research, Manas AI is on a mission to bring life-saving treatments to patients faster than ever before. Visit manasai.co for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415952246/en/
Contacts
Aria Finger
Aria@manasai.co
